Vertex Pharma (VRTX): "Triple Combination" Success More Likely - Leerink
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/13/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Jefferies Raises Price Target on Vertex Pharma (VRTX) to $107; Reiterates Buy
July 28, 2016 9:07 AM EDTJefferies reiterated a Buy rating on Vertex Pharma (NASDAQ: VRTX), and raised the price target to $107.00 (from $102.00), following the company's 2Q earnings report. Orkambi sales fell slightly short of $249M estimates. Vertex continues to expect persistence and compliance rates on... More
